Journal articlePreclinical
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Journal of neurochemistry, 2006 Apr. Dolotov OV, Karpenko EA, Seredenina TS and 7 others.
Study type
Journal article
Subjects
Animal / preclinical (no Humans MeSH term)
Journal
Journal of neurochemistry
Published
2006 Apr
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Administration, IntranasalAdrenocorticotropic HormoneAnimalsBrain-Derived Neurotrophic FactorCalciumCell MembraneCells, CulturedImmunoenzyme TechniquesMaleManganeseNeuroprotective AgentsPeptide Fragments
Other papers on N-Acetyl Semax Amidate
Clinical trial · 2018
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]
Journal article · 2021[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain]
Journal article · 2011[The effect of semax and its C-end peptide PGP on expression of the neurotrophins and their receptors in the rat brain during incomplete global ischemia]
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page